SCHEMBL26089925

SCHEMBL26089925

Cc1c(-c2cc3cnccc3[nH]2)cnn1C

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TTK P33981 1/20 0.49
CLK2 P49760 4/20 0.44
CLK3 P49761 4/20 0.44
DYRK1A Q13627 4/20 0.44
BRD4 O60885 2/20 0.41
HRH4 Q9H3N8 1/20 0.40
DAO P14920 1/20 0.40
KDM4C Q9H3R0 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
F3 P13726 3/20 0.36
MAPT P10636 1/20 0.36
SNCA P37840 1/20 0.36
F2 P00734 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP11B2 P19099 1/20 0.36
IDH1 O75874 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26086754 0.89 TTK (0.47) TTKCLK2CLK3DYRK1ABRD4
SCHEMBL26426622 0.71 PDE5A (0.52) BRD4KDM4CPDE3BPDE3A
SCHEMBL31691908 0.69 DAO (0.53) CLK2CLK3DYRK1AHRH4DAO
SCHEMBL4805509 0.69 DAO (0.53) CLK2CLK3DYRK1AHRH4DAO
SCHEMBL3837963 0.69 F3 (0.48) CLK2CLK3DYRK1ADAOF3
SCHEMBL29871364 0.69 F3 (0.48) CLK2CLK3DYRK1ADAOF3
SCHEMBL26089278 0.69 KDM4E (0.68) CLK2DYRK1AF3MAPT
SCHEMBL18450822 0.69 CLK2 (0.61) CLK2CLK3DYRK1ADAOMAPT
SCHEMBL8878252 0.67 CYP19A1 (0.63) CLK2CLK3DYRK1ADAOF3
SCHEMBL21241222 0.67 COMT (0.53) BRD4MAPTCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
CN-115175909-A Pyrrolopyridine and imidazopyridine antiviral compounds 鲁汶天主教大学 2022-10-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS SARS1, TPI1, TPMT TTK 2306/4885CLK2 2562/4885CLK3 2988/4885
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 TTK 1959/4885CLK2 4427/4885CLK3 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.